Molecular pathology of lung cancer: Key to personalized medicine

Liang Cheng, Riley E. Alexander, Gregory T. MacLennan, Oscar Cummings, Rodolfo Montironi, Antonio Lopez-Beltran, Harvey Cramer, Darrell Davidson, Shaobo Zhang

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not fully understood. Clinicopathological observations suggest that molecular alterations involving so-called 'driver mutations' could be used as markers that aid in the selection of patients most likely to benefit from targeted therapies. In this review, we summarize recent developments involving the specific molecular mechanisms and markers that have been associated with primary and acquired resistance to EGFR-targeted therapy in lung adenocarcinomas. Understanding these mechanisms may provide new treatment avenues and improve current treatment algorithms.

Original languageEnglish
Pages (from-to)347-369
Number of pages23
JournalModern Pathology
Volume25
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Precision Medicine
Molecular Pathology
Lung Neoplasms
Protein-Tyrosine Kinases
Therapeutics
Epidermal Growth Factor Receptor
Patient Selection
Mutation
Neoplasms

Keywords

  • EML4-ALK rearrangement
  • epidermal growth factor receptor (EGFR)
  • KRAS mutation
  • lung adenocarcinoma
  • molecular classification
  • personalized medicine
  • targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular pathology of lung cancer : Key to personalized medicine. / Cheng, Liang; Alexander, Riley E.; MacLennan, Gregory T.; Cummings, Oscar; Montironi, Rodolfo; Lopez-Beltran, Antonio; Cramer, Harvey; Davidson, Darrell; Zhang, Shaobo.

In: Modern Pathology, Vol. 25, No. 3, 03.2012, p. 347-369.

Research output: Contribution to journalArticle

Cheng, L, Alexander, RE, MacLennan, GT, Cummings, O, Montironi, R, Lopez-Beltran, A, Cramer, H, Davidson, D & Zhang, S 2012, 'Molecular pathology of lung cancer: Key to personalized medicine', Modern Pathology, vol. 25, no. 3, pp. 347-369. https://doi.org/10.1038/modpathol.2011.215
Cheng L, Alexander RE, MacLennan GT, Cummings O, Montironi R, Lopez-Beltran A et al. Molecular pathology of lung cancer: Key to personalized medicine. Modern Pathology. 2012 Mar;25(3):347-369. https://doi.org/10.1038/modpathol.2011.215
Cheng, Liang ; Alexander, Riley E. ; MacLennan, Gregory T. ; Cummings, Oscar ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; Cramer, Harvey ; Davidson, Darrell ; Zhang, Shaobo. / Molecular pathology of lung cancer : Key to personalized medicine. In: Modern Pathology. 2012 ; Vol. 25, No. 3. pp. 347-369.
@article{7a0659f7715c4c739b318ab4c1bcf56f,
title = "Molecular pathology of lung cancer: Key to personalized medicine",
abstract = "The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not fully understood. Clinicopathological observations suggest that molecular alterations involving so-called 'driver mutations' could be used as markers that aid in the selection of patients most likely to benefit from targeted therapies. In this review, we summarize recent developments involving the specific molecular mechanisms and markers that have been associated with primary and acquired resistance to EGFR-targeted therapy in lung adenocarcinomas. Understanding these mechanisms may provide new treatment avenues and improve current treatment algorithms.",
keywords = "EML4-ALK rearrangement, epidermal growth factor receptor (EGFR), KRAS mutation, lung adenocarcinoma, molecular classification, personalized medicine, targeted therapy",
author = "Liang Cheng and Alexander, {Riley E.} and MacLennan, {Gregory T.} and Oscar Cummings and Rodolfo Montironi and Antonio Lopez-Beltran and Harvey Cramer and Darrell Davidson and Shaobo Zhang",
year = "2012",
month = "3",
doi = "10.1038/modpathol.2011.215",
language = "English",
volume = "25",
pages = "347--369",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Molecular pathology of lung cancer

T2 - Key to personalized medicine

AU - Cheng, Liang

AU - Alexander, Riley E.

AU - MacLennan, Gregory T.

AU - Cummings, Oscar

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - Cramer, Harvey

AU - Davidson, Darrell

AU - Zhang, Shaobo

PY - 2012/3

Y1 - 2012/3

N2 - The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not fully understood. Clinicopathological observations suggest that molecular alterations involving so-called 'driver mutations' could be used as markers that aid in the selection of patients most likely to benefit from targeted therapies. In this review, we summarize recent developments involving the specific molecular mechanisms and markers that have been associated with primary and acquired resistance to EGFR-targeted therapy in lung adenocarcinomas. Understanding these mechanisms may provide new treatment avenues and improve current treatment algorithms.

AB - The majority of lung adenocarcinoma patients with epidermal growth factor receptor-(EGFR) mutated or EML4-ALK rearrangement-positive tumors are sensitive to tyrosine kinase inhibitors. Both primary and acquired resistance in a significant number of those patients to these therapies remains a major clinical problem. The specific molecular mechanisms associated with tyrosine kinase inhibitor resistance are not fully understood. Clinicopathological observations suggest that molecular alterations involving so-called 'driver mutations' could be used as markers that aid in the selection of patients most likely to benefit from targeted therapies. In this review, we summarize recent developments involving the specific molecular mechanisms and markers that have been associated with primary and acquired resistance to EGFR-targeted therapy in lung adenocarcinomas. Understanding these mechanisms may provide new treatment avenues and improve current treatment algorithms.

KW - EML4-ALK rearrangement

KW - epidermal growth factor receptor (EGFR)

KW - KRAS mutation

KW - lung adenocarcinoma

KW - molecular classification

KW - personalized medicine

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84862823259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862823259&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.215

DO - 10.1038/modpathol.2011.215

M3 - Article

C2 - 22282308

AN - SCOPUS:84862823259

VL - 25

SP - 347

EP - 369

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -